Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

Phase 2 Completed 37 enrolled Duke University Janssen Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

The addition of abiraterone acetate to standard treatment of radiotherapy and short-term androgen deprivation will increase the frequency of undetectable PSA.

Timeline

Start: 2014-01-17
Primary completion: 2017-08-24
Completion: 2021-08-31

Publications

Koontz BF, Hoffman KE, Halabi S, Healy P, Anand M, George DJ, Harrison MR, Zhang T, Berry WR, Corn PG, Lee WR, Armstrong AJ. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1271-1278. doi: 10.1016/j.ijrobp.2020.11.059. Epub 2020 Nov 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abiraterone acetate	Small molecule	1000 mg	Oral
Background	Goserelin	Other / unclassified	10.8 mg	Subcutaneous
Background	Leuprolide	Other / unclassified	22.5 mg	Intramuscular
Background	Prednisone	Other / unclassified	5 mg	—

Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications